Nanoscope Therapeutics Reports P-IIb Trial (RESTORE) Results of MCO-010 for the Treatment of Retinitis Pigmentosa
Shots:
- The P-IIb trial evaluating MCO-010 (IVT) vs PBO in 27 patients showed vision function improvements after treatment with MCO-010 & were consistent with prior studies with a favorable safety profile
- 88.9% vs 44.4% achieved a ≥2 luminance level improvement in MLYMT or MLSDT @12mos., 7 out of 18 improved by -0.3 LogMAR or more in BCVA vs 1 out of 9 in PBO, visual acuity gains were observed
- No serious or sev. ocular or systemic AEs were reported, 1 SAE in PBO treated patient with a comparable incidence of TEAEs across study arms & the (RESTORE) results are expected to present at upcoming medical conferences. MCO-010, an ambient-light activatable MCO optogenetic therapy for vision restoration has received ODD & FTD from the US FDA
Ref: Nanoscope Therapeutics | Image: Nanoscope Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
